• Overview
  • Eligibility
  • More info
  • Locations

An Evaluation of the Effect of Androgen Ablation on Bone Resorption in Prostate Cancer Patients (NCT00003903)

National Cancer Institute (NCI)
RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more comfortably. PURPOSE: Clinical trial to determine the effect of androgen suppression on bone loss in patients who have prostate cancer.
  • Procedure: management of therapy complications
    Ages eligible for Study
    Genders eligible for Study
    Accepts Healthy Volunteers

    - Evaluate the effect of androgen ablation on bone resorption in patients with or without bone metastases secondary to prostate cancer.

    OUTLINE: Patients are stratified according to prior androgen ablation therapy (yes vs no) and metastatic disease (yes vs no).

    Patients undergo blood work and 24 hour urine collection on day 1 and at week 6-8. Patients who have received androgen ablation therapy and are found to have increased bone resorption undergo a dual energy x-ray absorptiometry (DEXA) scan.

    A comparison is made between androgen ablation therapy and bone resorption and if metastases are associated with the two.

    PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study within 9 months.

    1 locations

    United States (1)
    • James P. Wilmot Cancer Center
      Not specified
      Rochester, New York, United States, 14642-0001
    30 June, 1999
    13 October, 2013
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!